Aceclofenac SR Tablet (Sustained Release) 200 mg

Aceclofenac SR Tablet (Sustained Release) is a specialized NSAID formulation containing 200 mg of Aceclofenac, designed for prolonged pain relief. Manufactured by Pharmik Laboratories Ltd, this tablet effectively manages osteoarthritis, rheumatoid arthritis, and dental pain. The sustained-release mechanism ensures 12-24 hour efficacy with single-dose convenience.

Priced at ৳8.00 per unit (৳80.00 per strip of 10), it offers cost-effective treatment. As a Sustained Release Tablet, it reduces dosing frequency while maintaining therapeutic drug levels. Patients report fewer gastrointestinal side effects compared to immediate-release NSAIDs.

Pharmacologically, Aceclofenac inhibits cyclooxygenase enzymes, blocking prostaglandin synthesis. This dual action reduces inflammation and pain perception. Studies show 90% oral bioavailability, making it faster-acting than traditional NSAIDs. Always consult doctors for dosage adjustments in hepatic impairment.

• Key indications: Ankylosing spondylitis, post-traumatic swelling
• Therapeutic class: NSAID for musculoskeletal disorders
• Storage: Protect from moisture at room temperature

Notable drug interactions include increased lithium toxicity risk. Avoid concurrent use with diuretics or anticoagulants. Pregnant women should prioritize safer alternatives after medical consultation. Mild side effects like dyspepsia typically resolve without intervention.

Take one 200 mg Sustained Release Tablet daily after meals. Re-evaluate after 2 weeks. Dose adjustment needed in renal/hepatic impairment.

Aceclofenac SR SR is a non-steroidal drug with anti-inflammatory and analgesic properties. It is a potent inhibitor of the enzyme cyclooxygenase, which is involved in the production of prostaglandin. After oral administration, it is rapidly and completely absorbed an unchanged drug.

Contraindicated in third trimester. Potentially harmful during lactation. Use in pregnancy only if benefits outweigh risks.

Monitor renal function during prolonged use. GI bleeding risk increases 5-fold with aspirin co-therapy.

Start with lowest effective dose in elderly. Avoid if CrCl <30 mL/min. Reduce dose by 50% in hepatic impairment.